News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2020

March

Media Release / Mar 17, 2020

Coronavirus disease (COVID-19) update

Read More
Media Release / Mar 03, 2020

Novartis receives Health Canada approval for MayzentTM (siponimod) to treat secondary progressive multiple sclerosis with active disease

Read More
2019

December

Media Release / Dec 16, 2019

British Columbia lists Tafinlar® plus Mekinist® for adjuvant treatment of melanoma patients with BRAF V600 mutation and lymph node involvement1

Read More
Media Release / Dec 12, 2019

Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)1

Read More

November

Media Release / Nov 20, 2019

Novartis establishes strategic alliance with Quebec artificial intelligence institute Mila

Read More
Media Release / Nov 19, 2019

Novartis in Canada named to 2019 Best Workplaces™ in Quebec

Read More

October

Media Release / Oct 23, 2019

Women living with metastatic breast cancer in British Columbia now have public access to KISQALI®

Read More
Media Release / Oct 09, 2019

Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel) i

Read More
Media Release / Oct 08, 2019

Targeted melanoma combination therapy Tafinlar® plus Mekinist® now reimbursed in Quebec for adjuvant melanoma patients with BRAF V600 mutation and lymph node involvement i

Read More

September

Media Release / Sep 26, 2019

Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer

Read More